浙富控股(002266.SZ):控股子公司中標合計10.26億元的多個工程項目
格隆匯3月15日丨浙富控股(002266.SZ)公佈,公司控股子公司四川華都核設備製造有限公司(“華都公司”)近日收到項目招標代理機構中核(上海)供應鏈管理有限公司出具的多份《中標通知書》,通知確定華都公司為多個工程項目招標採購項目的中標單位,交易對方為中國核動力研究設計院所屬成都核總核動力研究設計工程有限公司。雙方將盡快簽署正式採購合同。
此次中標總金額合計人民幣102590.66萬元,約佔公司2021年度營業收入的7.26%,按照72個月交貨期安排,平均佔2021年度營業收入的1.21%,公司將按照交貨進度生產部件並確認銷售收入,預計將增加公司2023-2029年的銷售收入和淨利潤。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.